SEC Filing Summary
Entity and period mismatch: The supplied filing is for Rosewind Corporation, not AYTU Biopharma, Inc. It is a Form 10-Q for the quarter ended November 30, 2012 (Rosewind’s fiscal 2013 first quarter), filed January 14, 2013. The figures below describe Rosewind and should not be attributed to AYTU.
Business context and reporting period
Rosewind described itself as a development-stage offshore sailing school, with operations centered on preparing and using a sailing vessel for student training. It reported only two students from whom it had collected full tuition as of the report date; cumulative revenue since inception was limited. The interim financial statements are unaudited.
Financial results and liquidity
| Metric | Quarter ended Nov. 30, 2012 | Prior-year quarter |
|---|---|---|
| Revenue | $0 | $0 |
| Operating expenses | $18,833 | $18,876 |
| Net loss | $19,859 | $19,667 |
| Operating cash used | $8,916 | $11,011 |
| Financing cash provided | $9,508 | $8,735 |
| Ending cash | $701 | $1,717 |
- At November 30, 2012, total assets were $11,876, current liabilities were $94,103, and shareholders’ deficit was $82,227. Management reported a working-capital deficit of $93,402.
- Current liabilities included $72,561 in related-party loans and $9,495 in accrued related-party interest. The loan to the sole officer and director bears 6% interest, is due on demand, and is secured by the sailing vessel.
- Quarterly loss increased $192, or approximately 1%, year over year. The company cited lower boat repair and maintenance and management expense, offset by higher professional fees and interest expense.
- Common shares outstanding rose to 4,889,402 from 4,856,068 at August 31, 2012. The company raised $5,000 through a common-stock issuance during the quarter.
Material changes, outlook, and risks
- Rosewind stated that available cash was insufficient to sustain the business and that it intended to seek additional equity funding. It cautioned that funding might not be available and disclosed substantial doubt about its ability to continue as a going concern.
- After quarter-end, on January 11, 2013, Rosewind signed a non-binding letter of intent with Glycomar Limited. The proposed transaction contemplated a $3 million fundraising for Glycomar’s drug-development program and issuance of 20 million Rosewind shares to acquire all outstanding Glycomar shares. Completion and terms were not assured.
- Key risks include minimal revenue and unproven demand, ongoing losses and cash needs, public-company compliance costs, dependence on one executive, related-party conflicts, vessel and operational hazards, uncertain regulatory requirements, and limited insurance. The company estimated public-company costs at over $25,000 annually.
- No quantified financial guidance was provided. Management said results for the quarter were not necessarily indicative of the fiscal year. It reported disclosure controls as effective and no material quarterly change in internal control over financial reporting.
Important facts for investors to verify
- Confirm the issuer: this filing identifies Rosewind Corporation, not AYTU Biopharma, Inc.
- Verify whether the Glycomar letter of intent led to a completed financing or acquisition, and review the final terms and share dilution.
- Assess the company’s ability to fund operations given $701 in quarter-end cash, a $93,402 working-capital deficit, and the demand nature of the related-party loan.
- Review subsequent filings for actual revenue, student bookings, vessel operating status, insurance coverage, and regulatory compliance.